Johnson & Johnson is waiting for word from the FDA on whether it’ll become the second diabetes med in its class to snag an approval for cardiovascular risk reduction. But in the meantime, it’s trumpeting more outcomes data to support its case.Original Article
ACC: Waiting on the FDA’s heart-helping verdict, J&J touts more positive CV data for Invokana
